LCM
ADCT icon

Lynx1 Capital Management’s ADC Therapeutics ADCT Stock Holding History

Lynx1 Capital Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,325,848
Closed -$5.3M – 23
2025
Q3 		$5.3M Buy
+1,325,848
New +$4.18M 1.08% 9

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Lynx1 Capital Management's ADCT Position: Q4 2025 in Review

Lynx1 Capital Management sold out of ADC Therapeutics (ADCT) in Q4 2025, closing a stake of 1,325,848 shares — an estimated $5.3M sold.

Lynx1 Capital Management first reported a position in ADCT in Q3 2025 and held it in 1 quarter. The position peaked at $5.3M in Q3 2025. 115 funds tracked by Wall St. Rank hold ADCT as of Q4 2025.

  • Lynx1 Capital Management reported no remaining ADC Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Lynx1 Capital Management sold 1,325,848 ADC Therapeutics shares in Q4 2025, an estimated $5.3M.
  • Lynx1 Capital Management first reported a position in ADC Therapeutics in Q3 2025 and held it in 1 quarter.
  • Lynx1 Capital Management's ADC Therapeutics position peaked at $5.3M in Q3 2025.
  • 115 funds tracked by Wall St. Rank held ADC Therapeutics as of Q4 2025.

Based on Lynx1 Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.